CYTK Q4 2023 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-14.6% YoY

Gross Profit

-$83M-4982.3% margin

Operating Income

-$127M-7620.7% margin

Net Income

-$137M-8187.6% margin

EPS (Diluted)

$-1.38

QoQ Revenue Growth

+342.3%

Cash Flow

Operating Cash Flow

-$74M

Free Cash Flow

-$74M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$824M

Total Liabilities

$1.2B

Stockholders' Equity

-$386M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	-14.6%
Gross Profit	-$83M	-$73M	-14.0%
Operating Income	-$127M	-$127M	-0.3%
Net Income	-$137M	-$137M	+0.4%

Revenue Segments

Milestone

$1M60%

Research And Development

$672,00040%